Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease by FAPI PET/CT and 5.0T-MRI

NCT07423013 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT07423013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07423013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease by FAPI PET/CT and 5.0T-MRI
Lead sponsor
Peking University Third Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
November 11, 2025
Completion date
May 31, 2027
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid eye disease